Pimobendan

Pimobendan

SCHEMBL14815175

COc1ccc(-c2nc3cc(C4=NNC(=O)C[C@@H]4C)ccc3[nH]2)cc1

nearest known ligand 0.84

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 6/20 0.84
PDE3A Q14432 6/20 0.84
ABCB11 O95342 1/20 0.84
MAOA P21397 1/20 0.84
ADORA2A P29274 1/20 0.84
GPR119 Q8TDV5 9/20 0.61
PDE4A P27815 2/20 0.58
PDE4B Q07343 2/20 0.58
PDE4C Q08493 2/20 0.58
PDE4D Q08499 2/20 0.58
KDM4E B2RXH2 3/20 0.55
ALDH1A1 P00352 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
F10 P00742 1/20 0.54
NPC1 O15118 1/20 0.48
PKM P14618 1/20 0.48
RAB9A P51151 1/20 0.48
MAPT P10636 1/20 0.47
CYP2C9 P11712 1/20 0.47
HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pimobendan SCHEMBL29386190 1.00 PDE3B (0.84) PDE3BPDE3AABCB11MAOAADORA2A
Pimobendan SCHEMBL27623 1.00 PDE3B (0.84) PDE3BPDE3AABCB11MAOAADORA2A
Pimobendan SCHEMBL15617988 1.00 PDE3B (0.84) PDE3BPDE3AABCB11MAOAADORA2A
Pimobendan SCHEMBL2466855 1.00 PDE3B (0.84) PDE3BPDE3AABCB11MAOAADORA2A
Pimobendan SCHEMBL668129 0.99 PDE3B (0.83) PDE3BPDE3AABCB11MAOAADORA2A
Pimobendan SCHEMBL1996787 0.99 PDE3B (0.83) PDE3BPDE3AABCB11MAOAADORA2A
Pimobendan SCHEMBL1997246 0.98 PDE3B (0.81) PDE3BPDE3AABCB11MAOAADORA2A
Pimobendan SCHEMBL1993626 0.95 PDE3B (0.77) PDE3BPDE3AABCB11MAOAADORA2A
Pimobendan SCHEMBL1649737 0.92 PDE3B (1.00) PDE3BPDE3AABCB11MAOAADORA2A
SCHEMBL9781454 0.87 PDE3B (0.64) PDE3BPDE3AABCB11MAOAADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3318247-A1 TASTE MASKED PHARMACEUTICAL COMPOSITION Boehringer Ingelheim Vetmedica GmbH (DE) 2018-05-09 EP claimed
EP-2741736-B1 TASTE MASKED PHARMACEUTICAL COMPOSITION BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2017-11-22 EP claimed
US-20140227351-A1 TASTE MASKED PHARMACEUTICAL COMPOSITION BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2014-08-14 US claimed
US-8741350-B2 Taste masked pharmaceutical composition BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2014-06-03 US claimed
US-20130084332-A1 TASTE MASKED PHARMACEUTICAL COMPOSITION BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2013-04-04 US claimed
EP-2825159-B1 PHARMACEUTICAL TABLET FORMULATION FOR THE VETERINARY MEDICAL SECTOR, METHOD OF PRODUCTION AND USE THEREOF BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2022-06-22 EP disclosed
US-11357855-B2 Liquid formulation Luoda Pharma Limited (IE) 2022-06-14 US disclosed
CN-109568253-B Liquid preparation 罗达制药有限公司 2022-04-26 CN disclosed
EP-3167876-B1 PHARMACEUTICAL TABLET FORMULATION FOR THE VETERINARY MEDICAL SECTOR, METHOD OF PRODUCTION AND USE THEREOF BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2021-09-08 EP disclosed
EP-3682902-A1 LIQUID FORMULATION Luoda Pharma Limited (IE) 2020-07-22 EP disclosed
EP-2849792-B1 LIQUID FORMULATION LUODA PHARMA LTD (IE) 2020-03-04 EP disclosed
US-10413610-B2 Liquid formulation Luoda Pharma Limited (IE) 2019-09-17 US disclosed
US-9808529-B2 Liquid formulation LUODA PHARMA PTY LTD (AU) 2017-11-07 US disclosed
EP-3167876-A1 PHARMACEUTICAL TABLET FORMULATION FOR THE VETERINARY MEDICAL SECTOR, METHOD OF PRODUCTION AND USE THEREOF Boehringer Ingelheim Vetmedica GmbH (DE) 2017-05-17 EP disclosed
US-9289390-B2 Taste masked pharmaceutical composition BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2016-03-22 US disclosed
US-20150148335-A1 LIQUID FORMULATION Luoda Pharma Limited (IE) 2015-05-28 US disclosed
US-20150064249-A1 PHARMACEUTICAL TABLET FORMULATION FOR THE VETERINARY MEDICAL SECTOR, METHOD OF PRODUCTION AND USE THEREOF BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2015-03-05 US disclosed
US-20140227351-A1 TASTE MASKED PHARMACEUTICAL COMPOSITION BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2014-08-14 US disclosed
US-8741350-B2 Taste masked pharmaceutical composition BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2014-06-03 US disclosed
US-20130084332-A1 TASTE MASKED PHARMACEUTICAL COMPOSITION BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2013-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150148335-A1 LIQUID FORMULATION ACE, AGTR1, AGT PDE3B 40/4885PDE3A 34/4885ABCB11 1969/4885
US-10413610-B2 Liquid formulation ACE, AGTR1, AGT PDE3B 40/4885PDE3A 34/4885ABCB11 1969/4885
US-11357855-B2 Liquid formulation ACE, AGTR1, AGT PDE3B 40/4885PDE3A 34/4885ABCB11 1969/4885
US-20150064249-A1 PHARMACEUTICAL TABLET FORMULATION FOR THE VETERINARY MEDICAL SECTOR, METHOD OF PRODUCTION AND USE THEREOF ACE, PIGS, ACE2 PDE3B 1008/4885PDE3A 582/4885ABCB11 34/4885
US-20130084332-A1 TASTE MASKED PHARMACEUTICAL COMPOSITION TAS2R50, TAS2R40, TAS2R42 PDE3B 779/4885PDE3A 579/4885ABCB11 765/4885
US-20140227351-A1 TASTE MASKED PHARMACEUTICAL COMPOSITION TAS2R50, TAS2R40, TAS2R30 PDE3B 985/4885PDE3A 674/4885ABCB11 842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.